FDA approves Revolution Medicines' pancreatic cancer drug

The FDA gave the green light to a highly anticipated pancreatic cancer treatment that has altered the prospects for patients facing the deadly disease. The agency on Wednesday approved Revolution Medicines’ daraxonrasib for second-line pancreatic ...